Intuitive Surgical is projected to report Q2 2026 revenue of $2.81 billion and non-GAAP EPS of $2.51 on July 28, with shares currently trading at $337.59 against an average analyst price target of $554.53.
Investors are primarily focused on the durability of worldwide da Vinci procedure growth, which analysts expect to land at roughly 15% year-over-year. This quarter’s results will be critical in evaluating the early adoption trajectory of the next-generation da Vinci 5 platform and its impact on capital equipment margins.
Furthermore, analysts are monitoring whether macroeconomic pressures or the rising use of GLP-1 weight-loss medications are causing significant headwinds in elective bariatric surgery volumes.